Jason Rushton
Director/Board Member presso Aria CV, Inc.
Profilo
Jason Rushton is currently a Director at Aria CV, Inc., Oncomyx Therapeutics, Inc., and a Partner at Xeraya Capital Sdn.
Bhd.
He was formerly an Independent Director at Liquidia Technologies, Inc. Rushton received both his undergraduate and graduate degrees from the University of Birmingham.
Posizioni attive di Jason Rushton
| Società | Posizione | Inizio |
|---|---|---|
Xeraya Capital Sdn. Bhd.
 Xeraya Capital Sdn. Bhd. Investment ManagersFinance Xeraya Capital Sdn. Bhd. (Xeraya Capital) is a venture capital firm founded in 2006 by Amirul Fares Wan Zahir. The firm is headquartered in Kuala Lumpur, Malaysia. | Private Equity Investor | - |
Oncomyx Therapeutics, Inc.
 Oncomyx Therapeutics, Inc. Packaged SoftwareTechnology Services Oncomyx Therapeutics, Inc. develops and operates software platform to orchestrate an immune response and treat cancer. Its platform's features include non-human pathogen, immuno-stimulatory, ability to multi-arm, and systemic delivery. The company was founded by Steve Potts, Michael Wood, Grant McFadden and is headquartered in Phoenix, AZ. | Director/Board Member | - |
Aria CV, Inc.
 Aria CV, Inc. Medical SpecialtiesHealth Technology Aria CV, Inc. develops medical devices. It designed to improve the lives of patients living with the disease of pulmonary hypertension. The company was founded by John Scandurra and Karl Vollmers in 20101 and is headquartered in St. Paul, MN. | Director/Board Member | - |
Precedenti posizioni note di Jason Rushton
| Società | Posizione | Fine |
|---|---|---|
Liquidia Technologies, Inc.
 Liquidia Technologies, Inc. Pharmaceuticals: MajorHealth Technology Liquidia Technologies, Inc. is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. It operates in two segments: Pharmaceutical Products and Partnering & Licensing. The two product candidates from its pipeline: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia Technologies was founded by Joseph M. DeSimone, Ashok K. Mendiratta, Edward T. Samulski, William R. Kenan, Ginger Denison and Jason Rolland in 2004 and is headquartered in Morrisville, NC. | Director/Board Member | - |
Formazione di Jason Rushton
| University of Birmingham | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 4 |
|---|---|
Liquidia Technologies, Inc.
Liquidia Technologies, Inc. Pharmaceuticals: MajorHealth Technology Liquidia Technologies, Inc. is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. It operates in two segments: Pharmaceutical Products and Partnering & Licensing. The two product candidates from its pipeline: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia Technologies was founded by Joseph M. DeSimone, Ashok K. Mendiratta, Edward T. Samulski, William R. Kenan, Ginger Denison and Jason Rolland in 2004 and is headquartered in Morrisville, NC. | Health Technology |
Aria CV, Inc.
Aria CV, Inc. Medical SpecialtiesHealth Technology Aria CV, Inc. develops medical devices. It designed to improve the lives of patients living with the disease of pulmonary hypertension. The company was founded by John Scandurra and Karl Vollmers in 20101 and is headquartered in St. Paul, MN. | Health Technology |
Xeraya Capital Sdn. Bhd.
Xeraya Capital Sdn. Bhd. Investment ManagersFinance Xeraya Capital Sdn. Bhd. (Xeraya Capital) is a venture capital firm founded in 2006 by Amirul Fares Wan Zahir. The firm is headquartered in Kuala Lumpur, Malaysia. | Finance |
Oncomyx Therapeutics, Inc.
Oncomyx Therapeutics, Inc. Packaged SoftwareTechnology Services Oncomyx Therapeutics, Inc. develops and operates software platform to orchestrate an immune response and treat cancer. Its platform's features include non-human pathogen, immuno-stimulatory, ability to multi-arm, and systemic delivery. The company was founded by Steve Potts, Michael Wood, Grant McFadden and is headquartered in Phoenix, AZ. | Technology Services |
- Borsa valori
- Insiders
- Jason Rushton
